Inequalities in pharmacologic treatment of spasticity in Sweden – health economic consequences of closing the treatment gap

Inequalities in pharmacologic treatment of spasticity in Sweden – health economic consequences of closing the treatment gap

Abstract Background The Swedish Healthcare Act states that patients should have equal access to healthcare. This study addresses at how this translates to pharmacological treatment of adult spasticity, including injections with botulinum toxin A (BoNT-A) and pumps for intrathecal baclofen (ITB). To...

Full description

Bibliographic Details
Main Authors: Annabelle Forsmark, Linda Rosengren, Per Ertzgaard
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Health Economics Review
Subjects:
Botulinum toxins
Baclofen
Muscle spasticity
Treatment
Access to health care
Health care costs
Online Access:https://doi.org/10.1186/s13561-020-0261-7

Internet

https://doi.org/10.1186/s13561-020-0261-7

Similar Items